Skip to main content
Erschienen in: BMC Gastroenterology 1/2018

Open Access 01.12.2018 | Research article

Feasibility of portal or superior mesenteric vein resection and reconstruction by allogeneic vein for pancreatic head cancer—a case-control study

Erschienen in: BMC Gastroenterology | Ausgabe 1/2018

Abstract

Background

There are few reports about resection of portal vein (PV)/superior mesenteric vein (SMV) and reconstruction by using allogeneic vein. This case-control study was designed to explore the feasibility and safety of this operation type in patients with T3 stage pancreatic head cancer.

Methods

A total of 42 patients (Group A) underwent PV/SMV resection and reconstruction by using allogeneic vein were 1:1 matched to 42 controls (Group B) with other types of resection and reconstruction. The two groups were well matched.

Results

There was no significantly prolonged total operation time (Group A vs. Group B [490.0 min vs. 470 min], P = 0.067) and increased intraoperative blood loss (Group A vs. Group B [650.0 min vs. 450 min], P = 0.108) was found between the two groups. R1 rate of PV/SMV was slightly reduced in group A compared to group B (4.8% vs. 14.3%, P = 0.137), although no significant difference was found. The incidences of main postoperative complications between the two groups were similar. A slightly increased 1-year and 2-year overall survival rate (OS) (Group A vs. Group B [1-year OS: 62.9% vs. 57.0%; 2-year OS: 31.5% vs. 25.6%], P = 0.501) and disease-free survival rate (DFS) (Group A vs. Group B [1-year DFS: 43.9% vs. 36.6%; 2-year DFS: 10.5% vs. 7.4%], P = 0.502) could be found in group A compared to group B, although the differences were not significant.

Conclusions

The operation types of PV/SMV resection and reconstruction by using allogeneic vein is safety and feasible, it might have a potential benefit for patients.
Abkürzungen
ASA
American Society of Anesthesiology
BMI
body mass index
CTA
Computed tomographic angiography
DFS
Disease-free survival rate
ISGPS
International Study Group of Pancreatic Surgery
OS
Overall survival rate
PD
Pancreatoduodenectomy
PV
Portal vein
SMV
Superior mesenteric vein

Background

With increasing incidence and mortality, cancer is the one of leading causes of death worldwide and it has become a major public problem. Among the malignant solid tumors, pancreatic cancer is characterized by low curative rate and high mortality [15]. Cancer Statistics in China which is completed by National Cancer Center of China shows that the estimated new cancer cases and deaths of pancreas are 90.1 and 79.4 thousand in 2015 [6]. Despite decades of effort, pancreatic cancer remains one of the most aggressive and lethal malignancies, and the five-year survival rate remains at only ~ 5% [7]. Due to biological characteristics of pancreatic cancer, also due to anatomical location of pancreas and lack of early detection tests, most of patients with localized disease have no recognizable symptoms or signs. As a result, only 15 to 25% of patients with pancreatic cancer is eligible for curative resection. Of the unresectable patients, approximately two thirds present with distant metastases and the rest presents with locally advanced disease which has surrounding vascular invasion. According to the TNM staging system of pancreatic cancer, tumor extending to portal vein (PV) or superior mesenteric vein (SMV) without involvement of celiac axis or superior mesenteric artery is defined as T3 stage. Based on performance status and preference of patients, and decision of Multi-Disciplinary Team, different therapeutic modalities including upfront surgery, neoadjuvant chemotherapy followed by surgery, chemotherapy alone, chemoradiotherapy, etc., can be selected for T3 stage pancreatic cancer which is clinically diagnosed. Of these modalities, upfront surgery is most frequently used.
Radical pancreatic surgery accompanied with PV/SMV resection, has commonly been undertaken for pancreatic cancer with infiltration of PV/SMV since the first report of pancreatoduodenectomy (PD) with resection and reanastomosis of vein in 1951 [8, 9]. Till now, there has been no consensus yet on the survival advantage of PV/SMV resection and reconstruction for pancreatic head cancer, although similar reported short-term outcomes when compared with standard PD [1013]. In the classification of International Study Group of Pancreatic Surgery (ISGPS), a total of four types of venous reconstruction are included [14]. With the view to improving the R0 resection rate, to reaching tension-free anastomosis, to avoiding the diameter mismatch between the PV and SMV, and also to avoiding vessel stenosis, segmental resection and reconstruction by using allogeneic vein has been preferred for selected patients since 2013 in our center.
In this study, we conducted a case-control study to explore the feasibility and safety of PV/SMV resection and reconstruction by using allogeneic vein in patients with pancreatic head adenocarcinoma.

Methods

Patients

From January 2012 to November 2016, patients with pancreatic head cancer who underwent surgical treatment at our institution were reviewed from our prospectively collected clinical database. Clinicopathological data of patients with duct adenocarcinoma of pancreatic head with PV/SMV infiltration by postoperative pathology were used for analysis. Patients with advanced pancreatic cancer, or with T4 stage pancreatic cancer, or without PV/SMV infiltration were excluded from this study, neither patients with cancer history nor patients with neoadjuvant therapy were enrolled in this study.
Patients underwent segmental PV/SMV resection with reconstruction using allogeneic vein were 1:1 matched with patients underwent PV/SMV resection with reconstruction by other methods (direct end-to-end anastomosis, partial venous excision with direct closure, partial venous excision using a patch or artificial vascular graft). Matching criteria included age, gender, body mass index (BMI), American Society of Anesthesiology (ASA) score, concomitant disease, blood test, surgical procedures (extended PD with extended Lymphadenectomy), postoperative pathology, and adjuvant therapy (Table 1). When investigators did the manual match, they were blinded to the surgical outcomes to reduce potential selection bias.
Table 1
General parameters of the two groups
Parameters
Group A (n = 42)
Group B (n = 42)
P-value
Gender, case (%)
  
0.826
 Male
18 (42.9)
19 (45.2)
 
 Female
24 (57.1)
23 (54.8)
 
Age, year, median (range)
68 (43–80)
67 (45–79)
0.952
BMI, kg/m2, median, (range)
21.5 (17.6–28.6)
23.1 (17.3–29.7)
0.238
ASA Score (%)
  
0.608
 2
11 (26.2)
9 (21.4)
 
 3
31 (73.8)
33 (78.6)
 
Concomitant disease, case (%)
32 (76.2)
33 (78.6)
0.794
Abdominal operation history, case (%)
4 (9.5)
3 (7.1)
0.693
Preoperative biliary drainage, case (%)
8 (19.0)
7 (16.7)
0.776
Hemoglobin, g/L, median (range)
112.5 (86–153)
112.0 (87–151)
0.673
Total bilirubin, μmol/l, median (range)
84.9 (10.1–440)
79.4 (19.9–423)
0.989
Direct bilirubin, μmol/l, median (range)
64.1 (6.3–347)
69.8 (12.8–367)
0.733
Carbohydrate antigen 19–9, U/ml, median (range)
511.5 (2.0–6021)
493.4 (2.1–5966)
0.834
Tumor size, cm, median (range)
3.5 (2.0–5.0)
3.3 (2.0–5.0)
0.557
Tumor differentiation, case (%)
  
0.903
 Well
2 (4.8)
2 (4.8)
 
 Moderate
24 (57.1)
22 (52.4)
 
 Poor
16 (38.1)
18 (42.9)
 
N stage, case (%)
  
0.728
 N0
4 (9.5)
5 (11.9)
 
 N1
38 (90.5)
37 (88.1)
 
Adjuvant therapy
  
0.977
 None
4 (9.5)
5 (11.9)
 
 Gemcitabine
14 (33.3)
12 (28.6)
 
 Gemcitabine+ Capecitabine
5 (11.9)
6 (14.3)
 
 S1
12 (28.6)
11 (26.2)
 
 FOLFIRINOX
7 (16.7)
8 (19.0)
 
ASA, American Society of Anesthesiology; BMI, body mass index; FOLFIRINOX, leucovorin and fluorouracil plus irinotecan and oxaliplatin

Surgical modality

In our center, four types of venous invasion were concluded. Type one, solid tumor contact with the PV/SMV of ≤90°; type two, solid tumor contact with the PV/SMV of > 90°, or obvious stenosis or occlusion of PV/SMV, without extension to confluence of splenic vein; type three, involvement of superior mesenteric-portal-splenic vein confluence; type four, involvement of both of superior mesenteric-portal-splenic vein confluence and branches of superior mesenteric vein. Patients with type one of PV/SMV invasion received partial venous excision with direct closure or partial venous excision using a patch, and patients with type two can received segmental PV/SMV resection with direct end-to-end anastomosis (length of invasion ≤2 cm) or reconstruction using allogeneic vein (length of invasion > 2 cm), whereas for patients with type three or type four, only segmental PV/SMV resection with reconstruction using allogeneic vein can be performed (Vascular reconstruction was completed for pancreatic head cancer with different type of venous invasion, as shown in Fig. 1).
According to the guidelines of ISGPS, standard PD combined with excision of PV/SMV could be defined as extended PD, and all patients underwent extended PD in this study; extended lymphadenectomy including the removal of lymph nodes of stations 5, 6, 8a, 8p, 9, 12a, 12p, 12b1, 12b2, 12c, 13a–b, 14a–d, 16a2, 16b1, and 17a–b was applied for all patients.

Postoperative management

Subcutaneous injection of nodroparin calcium 0.4 mL per day was started on the second day after operation and ended on the seventh days, then 1 month of oral aspirin was recommended. Doppler B-ultrasound was used for observing the venous blood flow on the third and seventh day after operation. Computed tomographic angiography (CTA) was used for justifying the condition of PV/SMV 1 month after operation, and then 6 months postoperatively; meanwhile Doppler was also used for evaluation of PV/SMV blood flow.

Parameters for analysis

Demographic and clinicopathologic parameters, operative details, perioperative complications and prognosis recorded to our database were used for analyzed. Drain amylase of > 3 times serum amylase after the third postoperative day, as defined by ISGPS [15], was defined as pancreatic fistula. The status of resection margins was classified based on the International Union Against Cancer R classification, as microscopic radical resection (R0), microscopic positive (R1), or gross positive (R2). Margin < 1 mm was defined as positive margin. Postoperative complications were monitored for 30 days after surgery, and perioperative mortality was defined as death within 30 days after surgery or during hospital stay.

Follow-up and statistical analysis

Physical examination, laboratory tests, and image examinations were used for follow-up, the follow-up interval was 2 months. SPSS 16.0 (IBM, Chicago, Illinois, USA) was used for data analysis. Quantitative variables were expressed as median and range, and comparisons were analyzed with the Student t-test according to data distribution. Categorical variables were presented as number and percentage and were analyzed by chi-square test or Fisher exact test, as appropriate. Kaplan-Meier method was used to analyze the survival of patients, and the curve of survival between groups was analyzed by log-rank test.

Results

As shown in Fig. 2, from January 2012 to November 2016, a total of 348 patients underwent extended PD in our hospital. Of these patients, 269 cases were confirmed as duct adenocarcinoma of pancreatic head by postoperative pathology. According to the TNM staging of pancreatic cancer of American Joint Committee on Cancer (AJCC), 184 cases had the T3 stage duct adenocarcinoma. 42 received segmental PV/SMV resection with reconstruction using allogeneic vein in all of the 184 patients. Of the 42 patients, type 2 PV/SMV invasion was confirmed in 32 cases, type three in 8 cases, and type four in 2 cases according to our classification of venous invasion (group A).
Patients with reconstruction using allogeneic vein (group A) were 1:1 matched to patients with reconstruction by other methods including segmental excision with direct end-to-end anastomosis, partial venous excision with direct closure, partial venous excision using a patch and segmental excision with artificial vascular graft (group B). In group B, type 1 PV/SMV invasion was confirmed in 17 patients and type two in 25 patients according to our classification of venous invasion. Of the 42 patients, 13 cases received partial venous excision with direct closure, four cases received partial venous excision using a patch, 22 cases received segmental excision with direct end-to-end anastomosis, and three cases received segmental excision with artificial vascular graft. Demographics and clinical characteristics are shown in Table 2. The two groups were well balanced in terms of age, gender, BMI, ASA score, concomitant disease, blood test, postoperative pathology, and adjuvant therapy (Table 1).
Table 2
Operation outcomes and long-term outcomes of the two groups
Parameters
Group A (n = 42)
Group B (n = 42)
P-value
Operation time, min, median (range)
490.0 (360.0–920.0)
470 (280.0–650.0)
0.067
Time to vein reconstruction, min, median (range)
52.5 (40.0–80.0)
45.0 (30.0–70.0)
< 0.001
Intraoperative blood loss, ml, median (range)
650.0 (350.0–1650.0)
450.0 (250.0–1350.0)
0.108
Lymph node retrieved
18.5 (7.0–50.0)
18.0 (6.0–46.0)
0.278
Length of vein resected, cm, median (range)
3.0 (2.0–6.0)
2.0 (1.0–4.0)
< 0.001
R1 rate of PV/SMV
2 (4.8)
6 (14.3)
0.137
Postoperative complications, case (%)
   
 Pancreatic fistula
6 (14.3)
8 (19.0)
0.558
 Bleed
2 (4.8)
2 (4.8)
1.000
 Delayed gastric emptying
5 (11.9)
4 (9.5)
0.724
 Portal vein thrombosis
0
1 (2.4)
0.314
OS, %
  
0.501
 1-year OS
62.9
57.0
 
 2-year OS
31.5
25.6
 
 3-year OS
0
0
 
DFS, %
  
0.502
 1-year DFS
43.9
36.6
 
 2-year DFS
10.5
7.4
 
DFS, disease-free survival rate; OS, overall survival rate
As shown in Table 2, there was no statistically significant difference was found for operation time between the two groups (490 min vs. 470 min, P = 0.067), although the time to vein reconstruction in group A was longer compared with that in group B (52.5 min vs. 45 min, P < 0.001). The volume of intraoperative blood loss was 650 mL and 450 mL in group A and group B, respectively (P = 0.108). The length of PV/SMV resected was measured in this study, and the median length was 3.0 cm in group A which was obviously longer than that in group B. Although no significant difference for the R1 rate of PV/SMV, the R1 rate decreased almost 10% in group A compared with group B (4.8% vs. 14.3%). The incidences of pancreatic fistula were 14.3 and 19.0%, no significant difference was found (P = 0.558), the same result could be found for incidence of bleed (4.8% vs. 4.8%). The stump bleeding of gastroduodenal artery was confirmed for all four patients. Emergency laparotomy was carried out for two patients, interventional embolization was used for another two patients, and none died from bleed. No portal vein thrombosis was found by doppler on the third and seventh day after operation in group A, but one patient had portal vein thrombosis conformed by doppler B-ultrasound. There was no patient with infectious complication related to allogeneic vein.
As shown in Fig. 3, the 1- and 2-year OS were 62.9 and 31.5% in group A, and 57.0 and 25.6% in group B (P = 0.501). The 1- and 2-year DFS were 43.9 and 10.5% in group A, 36.6 and 7.4% in group B, respectively (P = 0.502), which were shown in Fig. 4. Neither group A nor group B had 3-year OS.

Discussion

Radical resection is still the only potential method for the cure of pancreatic cancer although the development of non-surgical fields [1618]. There is no unanimous consensus yet on the efficacy of vascular resection for pancreatic cancer with infiltration of PV/SMV [1921]. Recently, the argument about the value of PV/SMV resection has become more and more prevalent [22]. As an example, a study designed by Murakami Y et al. [12]. Showed that PD with PV/SMV resection and adjuvant chemotherapy in patients with pancreatic head carcinoma might provide good survival without increased mortality and morbidity; whereas a meta-analysis designed by F. Giovinazzo et al. [10]. Revealed that inferior results including increased postoperative mortality, higher rates of non-radical surgery and worse survival were related to PV/SMV resection. Especially to deserve to be mentioned, these two articles were published in the same journal during a short interval. Although the widespread growth of controversy, PV/SMV resection and reconstruction has been still recommended by some centers [9, 2225].
Four types of venous resection are recommended by ISGPS [14]: partial venous excision with direct closure (venorraphy) by suture closure; partial venous excision using a patch; segmental resection with primary venovenous anastomosis; segmental resection with interposed venous conduit and at least two anastomoses. We think that partial venous excision with direct closure or using a patch may be feasible when venous infiltration is less than 90°, whereas it is not suitable when involvement of PV/SMV is more than 90°. Two main related drawbacks are vessel stenosis and increased R0 rate. We also suggest that segmental resection with direct venovenous anastomosis is preferred when length of invasion ≤2 cm with venous involvement > 90°, direct end-to-end anastomosis may not be the best choice if the length of venous invasion > 2 cm. The disadvantages of end-to-end anastomosis mainly includes increased tension of blood vessel and diameter mismatch. For some infiltration of special location such as superior mesenteric-portal-splenic vein confluence, neither direct end-to-end anastomosis nor artificial blood vessel is suitable. Venous resection and reconstruction by using allogeneic vein may provide an alternative way.
Compared with routine venous resection and reconstruction, the coexistence of advantages and disadvantages can be observed for allogeneic vein reconstruction. We conclude the main advantages of this technique: Firstly, extending surgical indications of pancreatic cancer. Without excessive limitation by infiltration scope of PV/SMV, patients have more chance to receive surgical resection. In our study, we could see that the length of PV/SMV resected in group A was obviously longer than group B. Secondly, improving en-bloc resection rate and R0 rate, more patients can benefit from radical resection. In this study, R1 rate of PV/SMV in group A decreased by nearly 10% compared with that in group B although no significant difference. Thirdly, avoiding incidences of vascular tension after anastomosis, vascular stenosis, anastomotic stricture and diameter mismatch. Recovering normal anatomic structure of vascular for special location such as superior mesenteric-portal-splenic vein confluence to the most extent. Fourthly, avoiding rejection induced by artificial vascular and long-time anticoagulation treatment.
The main disadvantages of this technique are easily observed. Obviously, the procedure of allogeneic vein reconstruction is more complex compared with routine types, thus more operation time is needed. In this study, we could see that the time to vein reconstruction was significantly longer in group A than that in group B, whereas the total operation time and intraoperative blood loss between the two groups were comparable. Preservation of blood vessel is another issue of concern, there has been no unified standard till now.
The complications did not increase in patients underwent allogeneic vein reconstruction, and no increased vein-related complications were found; meanwhile, the prognosis in these patients had slight improvement although no significant difference.

Conclusions

PV/SMV resection and reconstruction by using allogeneic vein is safety and feasible, it may extend surgical indications and increase R0 resection rate compared with routine types.

Acknowledgements

All authors thank Dai Yang and Zhang Xin-xue for supporting data, their supports are the key factor for completion of this manuscript.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
This study was reviewed and approved by the Ethics Committee of Beijing Chaoyang Hospital. Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Zhang XM, Fan H, Kou JT, Zhang XX, Li P, Dai Y, et al. Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer. J Gastroenterol Hepatol. 2016;31:1498–503.CrossRefPubMed Zhang XM, Fan H, Kou JT, Zhang XX, Li P, Dai Y, et al. Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer. J Gastroenterol Hepatol. 2016;31:1498–503.CrossRefPubMed
2.
Zurück zum Zitat Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122:2158–67.CrossRefPubMed Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122:2158–67.CrossRefPubMed
3.
Zurück zum Zitat Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed
4.
Zurück zum Zitat Baker H. Surveillance benefit for pancreatic cancer in high-risk individuals. Lancet Oncol. 2016;17:e227.CrossRefPubMed Baker H. Surveillance benefit for pancreatic cancer in high-risk individuals. Lancet Oncol. 2016;17:e227.CrossRefPubMed
5.
Zurück zum Zitat Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of surveillance for pancreatic Cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol. 2016;34:2010–9.CrossRefPubMed Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of surveillance for pancreatic Cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol. 2016;34:2010–9.CrossRefPubMed
6.
Zurück zum Zitat Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
7.
Zurück zum Zitat Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.CrossRefPubMedPubMedCentral Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Moore GE, Sako Y, Thomas LB. Radical pancreatoduodenectomy with resection and reanastomosis of the superior mesenteric vein. Surgery. 1951;30:550–3.PubMed Moore GE, Sako Y, Thomas LB. Radical pancreatoduodenectomy with resection and reanastomosis of the superior mesenteric vein. Surgery. 1951;30:550–3.PubMed
9.
Zurück zum Zitat Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42:1004–10.CrossRefPubMed Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42:1004–10.CrossRefPubMed
10.
Zurück zum Zitat Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103:179–91.CrossRefPubMed Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103:179–91.CrossRefPubMed
11.
Zurück zum Zitat Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol. 2014;40:371–8.CrossRefPubMed Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol. 2014;40:371–8.CrossRefPubMed
12.
Zurück zum Zitat Murakami Y, Satoi S, Motoi F, Sho M, Kawai M, Matsumoto I, et al. Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma. Br J Surg. 2015;102:837–46.CrossRefPubMed Murakami Y, Satoi S, Motoi F, Sho M, Kawai M, Matsumoto I, et al. Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma. Br J Surg. 2015;102:837–46.CrossRefPubMed
13.
Zurück zum Zitat Han SS, Park SJ, Kim SH, Cho SY, Kim YK, Kim TH, et al. Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer. Pancreas. 2012;41:102–6.CrossRefPubMed Han SS, Park SJ, Kim SH, Cho SY, Kim YK, Kim TH, et al. Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer. Pancreas. 2012;41:102–6.CrossRefPubMed
14.
Zurück zum Zitat Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the international study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.CrossRefPubMed Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the international study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.CrossRefPubMed
15.
Zurück zum Zitat Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.CrossRefPubMed Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.CrossRefPubMed
16.
Zurück zum Zitat Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46.CrossRefPubMed Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46.CrossRefPubMed
17.
Zurück zum Zitat Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10–22.CrossRefPubMed Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10–22.CrossRefPubMed
18.
Zurück zum Zitat Dasari BV, Pasquali S, Vohra RS, Smith AM, Taylor MA, Sutcliffe RP, et al. Extended versus standard lymphadenectomy for pancreatic head Cancer: meta-analysis of randomized controlled trials. J Gastrointest Surg. 2015;19:1725–32.CrossRefPubMed Dasari BV, Pasquali S, Vohra RS, Smith AM, Taylor MA, Sutcliffe RP, et al. Extended versus standard lymphadenectomy for pancreatic head Cancer: meta-analysis of randomized controlled trials. J Gastrointest Surg. 2015;19:1725–32.CrossRefPubMed
20.
Zurück zum Zitat Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36:884–91.CrossRefPubMed Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36:884–91.CrossRefPubMed
21.
Zurück zum Zitat Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg. 2011;98:86–92.CrossRefPubMed Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg. 2011;98:86–92.CrossRefPubMed
22.
Zurück zum Zitat Ramacciato G, Nigri G, Petrucciani N, Pinna AD, Ravaioli M, Jovine E, et al. Pancreatectomy with mesenteric and portal vein resection for borderline Resectable pancreatic Cancer: multicenter study of 406 patients. Ann Surg Oncol. 2016;23:2028–37.CrossRefPubMed Ramacciato G, Nigri G, Petrucciani N, Pinna AD, Ravaioli M, Jovine E, et al. Pancreatectomy with mesenteric and portal vein resection for borderline Resectable pancreatic Cancer: multicenter study of 406 patients. Ann Surg Oncol. 2016;23:2028–37.CrossRefPubMed
23.
Zurück zum Zitat Wang WL, Ye S, Yan S, Shen Y, Zhang M, Wu J, et al. Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion. Hepatobiliary Pancreat Dis Int. 2015;14:429–35.CrossRefPubMed Wang WL, Ye S, Yan S, Shen Y, Zhang M, Wu J, et al. Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion. Hepatobiliary Pancreat Dis Int. 2015;14:429–35.CrossRefPubMed
24.
Zurück zum Zitat Kim PT, Wei AC, Atenafu EG, Cavallucci D, Cleary SP, Moulton CA, et al. Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma. Br J Surg. 2013;100:1349–56.CrossRefPubMed Kim PT, Wei AC, Atenafu EG, Cavallucci D, Cleary SP, Moulton CA, et al. Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma. Br J Surg. 2013;100:1349–56.CrossRefPubMed
25.
Zurück zum Zitat Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218:401–11.CrossRefPubMed Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218:401–11.CrossRefPubMed
Metadaten
Titel
Feasibility of portal or superior mesenteric vein resection and reconstruction by allogeneic vein for pancreatic head cancer—a case-control study
Publikationsdatum
01.12.2018
Erschienen in
BMC Gastroenterology / Ausgabe 1/2018
Elektronische ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-018-0778-y

Weitere Artikel der Ausgabe 1/2018

BMC Gastroenterology 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.